Investigational drug · Phase 3
Ziltivekimab
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
11
Any phase or sponsor naming "Ziltivekimab"
First trial start
2024
Apr 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ziltivekimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myocardial Infarction (AMI)
- Myocardial Infarction
- Heart Failure
- Systemic Inflammation
- Cardiovascular Risk
- Coronary Artery Disease
- Coronary Atherosclerosis of Native Coronary Artery
Approved drugs for the same conditions: Heart failure · Coronary artery disease and heart attack · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Ziltivekimab" as an intervention, largest first.
- ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06118281 · 10,000 participants (planned) · Start Jun 25, 2024 · Primary completion Jan 29, 2027
Drug: Ziltivekimab; Placebo · For: Cardiovascular Risk; Acute Myocardial Infarction (AMI)
Sites: Alexander City, Alabama; Birmingham, Alabama; Fairhope, Alabama · 836 sites in all
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05021835 · 6,385 participants · Start Aug 30, 2021 · Primary completion Jun 9, 2026
Drug: Ziltivekimab B; Ziltivekimab C and 2 more · For: Cardiovascular Risk; Chronic Kidney Disease; Inflammation
Sites: Birmingham, Alabama; Montgomery, Alabama; Glendale, Arizona · 1,073 sites in all
- A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationPivotal-lookingTerminated
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05636176 · 4,874 participants · Start May 8, 2023 · Primary completion Sep 3, 2026
Drug: Ziltivekimab; Placebo · For: Heart Failure
Sites: Alexander City, Alabama; Fairhope, Alabama; Huntsville, Alabama · 1,013 sites in all
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06200207 · 673 participants (planned) · Start Apr 1, 2024 · Primary completion Oct 1, 2026
Drug: Ziltivekimab; Placebo · For: Heart Failure; Systemic Inflammation
Sites: Alexander City, Alabama; Fairhope, Alabama; Little Rock, Arkansas · 217 sites in all
- A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart AttackPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07301034 · 332 participants (planned) · Start Dec 18, 2025 · Primary completion Nov 14, 2028
Drug: Ziltivekimab; Ziltivekimab Placebo · For: Myocardial Infarction
Sites: Vienna, Austria; Gistrup, Denmark; København Ø, Denmark · 20 sites in all
- Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial InfarctionPivotal-lookingRecruiting
ECRI bvIndustry
NCT07276282 · 332 participants (planned) · Start Dec 19, 2025 · Primary completion Sep 1, 2028
Drug: Ziltivekimab; Placebo · For: Coronary Artery Disease; Acute Myocardial Infarction (AMI); Coronary Atherosclerosis of Native Coronary Artery
Sites: Bern, Switzerland
- A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine ZiltivekimabPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05721989 · 267 participants · Start Feb 3, 2023 · Primary completion Jan 8, 2024
Drug: Ziltivekimab B; Ziltivekimab D and 1 more · For: Healthy Participants
Sites: Budapest, Hungary; Groningen, Netherlands
- Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 InhibitionPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03926117 · 264 participants · Start Jun 3, 2019 · Primary completion Jun 26, 2020
Drug: Ziltivekimab · For: Chronic Kidney Diseases; Inflammation
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 49 sites in all
- Specifying the Anti-inflammatory Effects of ZiltivekimabPivotal-lookingCompleted
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
NCT06263244 · 40 participants · Start May 3, 2024 · Primary completion Oct 30, 2026
Drug: Ziltivekimab; Placebo · For: Atherosclerosis; Inflammation
Sites: Amsterdam, Netherlands
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04626505 · 36 participants · Start Oct 22, 2020 · Primary completion Aug 3, 2021
Drug: Ziltivekimab; Placebo (ziltivekimab) · For: Chronic Kidney Disease; Inflammation; Cardiovascular Risk
Sites: Ehime, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease.
Ridker PM, Lincoff AM, Marx N, et al. · N Engl J Med 2026
- The odyssey of inflammation: pericoronary adipose tissue attenuation as a dynamic marker of coronary-specific inflammation.
Avivi I, Taub PR, Ben-Yehuda O · Curr Opin Cardiol 2026
- Correction to: Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials.
· Eur J Heart Fail 2026
- High sensitivity C-reactive protein and the risk of cardio-kidney outcomes in adults with moderate to severe chronic kidney disease: a nationwide study.
Mazhar F, Han M, Tuttle KR, et al. · Nephrol Dial Transplant 2026
- High-sensitivity C-Reactive Protein as a Risk-Enhancing Biomarker in Patients with Chronic Kidney Disease and Atherosclerotic Cardiovascular Disease: A Narrative Review.
Prakash N S G, Devasia T, Paramasivam G, et al. · Cardiorenal Med 2026
- The Comorbidity-Driven Interleukin-6-Mediated Systemic Inflammation Hypothesis of Heart Failure With Preserved Ejection Fraction: A Decade of Testing Ends in Disappointment.
Packer M, Butler J, Zannad F, et al. · J Card Fail 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.